JP2010270124A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010270124A5 JP2010270124A5 JP2010151115A JP2010151115A JP2010270124A5 JP 2010270124 A5 JP2010270124 A5 JP 2010270124A5 JP 2010151115 A JP2010151115 A JP 2010151115A JP 2010151115 A JP2010151115 A JP 2010151115A JP 2010270124 A5 JP2010270124 A5 JP 2010270124A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- dmxaa
- dimethylxanthenone
- acetic acid
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 4
- 229960004316 cisplatin Drugs 0.000 claims 4
- 230000002708 enhancing effect Effects 0.000 claims 4
- 230000001747 exhibiting effect Effects 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229950008737 vadimezan Drugs 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0121285.1A GB0121285D0 (en) | 2001-09-03 | 2001-09-03 | Anti-cancer combinations |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524567A Division JP2005509599A (ja) | 2001-09-03 | 2002-09-03 | 抗癌組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010270124A JP2010270124A (ja) | 2010-12-02 |
| JP2010270124A5 true JP2010270124A5 (enExample) | 2011-01-20 |
Family
ID=9921418
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524567A Ceased JP2005509599A (ja) | 2001-09-03 | 2002-09-03 | 抗癌組み合わせ |
| JP2009133903A Pending JP2009263371A (ja) | 2001-09-03 | 2009-06-03 | 抗癌組み合わせ |
| JP2010151115A Pending JP2010270124A (ja) | 2001-09-03 | 2010-07-01 | 抗癌組み合わせ |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524567A Ceased JP2005509599A (ja) | 2001-09-03 | 2002-09-03 | 抗癌組み合わせ |
| JP2009133903A Pending JP2009263371A (ja) | 2001-09-03 | 2009-06-03 | 抗癌組み合わせ |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US7863322B2 (enExample) |
| EP (3) | EP2236134A1 (enExample) |
| JP (3) | JP2005509599A (enExample) |
| CN (5) | CN101607087A (enExample) |
| AT (1) | ATE415963T1 (enExample) |
| AU (1) | AU2002324143B2 (enExample) |
| BR (1) | BR0212258A (enExample) |
| CA (1) | CA2458459A1 (enExample) |
| CY (1) | CY1110426T1 (enExample) |
| DE (1) | DE60230159D1 (enExample) |
| DK (1) | DK1423105T3 (enExample) |
| EA (3) | EA200801611A1 (enExample) |
| ES (1) | ES2321283T3 (enExample) |
| GB (1) | GB0121285D0 (enExample) |
| IL (1) | IL160178A0 (enExample) |
| IS (1) | IS7144A (enExample) |
| MX (1) | MXPA04002004A (enExample) |
| NO (1) | NO20040591L (enExample) |
| NZ (5) | NZ567456A (enExample) |
| PT (1) | PT1423105E (enExample) |
| SI (1) | SI1423105T1 (enExample) |
| WO (1) | WO2003020259A2 (enExample) |
| ZA (1) | ZA200401078B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164077A (en) | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| ATE324888T1 (de) * | 1999-06-14 | 2006-06-15 | Cancer Rec Tech Ltd | Krebstherapie |
| MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| EP1311262A4 (en) | 2000-07-28 | 2005-06-01 | Cancer Rec Tech Ltd | COMBINED TREATMENT AGAINST CANCER |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB0202544D0 (en) | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
| GB2386836B (en) | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| GB0321999D0 (en) * | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
| CA2544320A1 (en) | 2003-11-13 | 2005-06-02 | Pharma Mar, S.A.U. | Method of treating cancer using a combination comprising et-743 and 5-fluorouracil |
| KR101188691B1 (ko) | 2004-10-29 | 2012-10-09 | 파르마 마르 에스.에이. | 엑티나시딘 및 디사카라이드를 포함하는 제제 |
| GB0517387D0 (en) * | 2005-08-26 | 2005-10-05 | Antisoma Res Ltd | Combinations for the treatment of cancer |
| CA2620436A1 (en) * | 2005-08-26 | 2007-03-01 | Antisoma Plc | Combinations comprising dmxaa for the treatment of cancer |
| GB0522082D0 (en) | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| GB0625283D0 (en) * | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| EP2231147A2 (en) * | 2007-12-13 | 2010-09-29 | Novartis AG | Combinations of therapeutic agents for treating cancer |
| CN101279967B (zh) * | 2008-05-29 | 2010-11-10 | 武汉远大制药集团有限公司 | 一种治疗癌症的三甲基呫吨酮-4-乙酸药物组合物及其用途 |
| RS54233B1 (sr) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | Kompozicije pd-1 antagonista i postupci za njihovu primenu |
| US20100068302A1 (en) * | 2008-09-17 | 2010-03-18 | Traslational Cancer Drugs Pharma, S.L. | Methods and compositions for the treatment of cancer |
| US20120129895A1 (en) * | 2009-08-11 | 2012-05-24 | Colleen Conway | Methods of treatment |
| DK2582847T3 (en) | 2010-06-18 | 2016-12-19 | Myriad Genetics Inc | METHODS AND MATERIALS TO ASSESS loss of heterozygosity |
| WO2012027224A1 (en) | 2010-08-24 | 2012-03-01 | Dana-Farber Cancer Institute, Inc. | Methods for predicting anti-cancer response |
| CN102786509B (zh) * | 2011-05-16 | 2016-06-01 | 杭州民生药业有限公司 | 2-(5,6-二甲基呫吨酮-4-基)-乙酸的衍生物及其制备方法和用途 |
| EP4563709A3 (en) | 2011-06-17 | 2025-09-03 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| EP2794907B2 (en) | 2011-12-21 | 2022-11-23 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| EP2617421A1 (en) * | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer |
| CA2864481C (en) | 2012-02-23 | 2020-07-14 | Dana-Farber Cancer Institute, Inc. | Methods for predicting anti-cancer response |
| WO2013182645A1 (en) | 2012-06-07 | 2013-12-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| US10308986B2 (en) | 2013-03-14 | 2019-06-04 | Children's Medical Center Corporation | Cancer diagnosis, treatment selection and treatment |
| EP3693475A1 (en) | 2013-04-05 | 2020-08-12 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| US20160067182A1 (en) * | 2013-04-09 | 2016-03-10 | Merrimack Pharmaceuticals, Inc. | Methods and compositions for improving outcomes of liposomal chemotherapy |
| US20160287623A1 (en) * | 2013-11-19 | 2016-10-06 | The University Of Chicago | Use of sting agonist as cancer treatment |
| CA2931181C (en) | 2013-12-09 | 2023-01-24 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| JP6877334B2 (ja) | 2014-08-15 | 2021-05-26 | ミリアド・ジェネティックス・インコーポレイテッド | 相同組換え欠損を評価するための方法および材料 |
| EP4141127B1 (en) | 2021-08-30 | 2024-10-09 | Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln | Method for assessing homologous recombination deficiency in ovarian cancer cells |
| CN115282140B (zh) * | 2022-02-07 | 2024-03-08 | 南京市儿童医院 | Aki治疗剂及dmxaa在制备该治疗剂中的应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3655470A (en) * | 1969-03-29 | 1972-04-11 | Toa Gosei Chem Ind | Process for the production of a foamed thermoplastic resin sheet |
| DE2015265A1 (de) | 1969-03-29 | 1970-10-08 | Yoshitomi Pharmaceutical Industries Ltd., Osaka (Japan) | Arylalkansäuren und Verfahren zu deren Herstellung |
| US4565806A (en) * | 1981-08-18 | 1986-01-21 | Setaelae Kai M E | Composition and method for rational treatment of cancer |
| FR2516922A1 (fr) * | 1981-11-25 | 1983-05-27 | Lipha | Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant |
| CA1264738A (en) * | 1984-12-04 | 1990-01-23 | Eli Lilly And Company | Treatment of tumors in mammals |
| US4704355A (en) * | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| US5281620A (en) * | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
| EP0278176B1 (en) | 1986-12-23 | 1994-03-09 | Warner-Lambert Company | Compounds having antitumour and antibacterial properties |
| JPH01193227A (ja) | 1988-01-29 | 1989-08-03 | Res Dev Corp Of Japan | 癌免疫療法補助剤 |
| US5126129A (en) * | 1988-05-23 | 1992-06-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Cancer therapy using interleukin-2 and flavone compounds |
| US5075287A (en) | 1989-03-03 | 1991-12-24 | Nisshin Oil Mills, Inc. | Muramyl peptide derivatives and immunoregulating compositions containing them |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| US5250296A (en) | 1990-11-29 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine |
| EP0551200A1 (en) | 1992-01-07 | 1993-07-14 | National University Of Singapore | Protein phosphatase inhibitors for use in therapy |
| CA2086874E (en) | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
| GB9308166D0 (en) * | 1993-04-20 | 1993-06-02 | Cancer Res Campaign Tech | Cancer therapy |
| GB9320484D0 (en) | 1993-10-05 | 1993-11-24 | Wellcome Found | Pharmaceutical combinations |
| DE4417742A1 (de) * | 1994-05-20 | 1995-11-23 | Bayer Ag | Nicht-systemische Bekämpfung von Parasiten |
| US5620875A (en) * | 1995-02-17 | 1997-04-15 | University Of Portland | Transfer of taxol from yew tree cuttings into a culture medium over time |
| WO1996032418A1 (en) | 1995-04-13 | 1996-10-17 | Laboratoires Om S.A. | Anti-cd14 antibodies for use in the induction of il-10 secretion |
| AU5857296A (en) | 1995-05-17 | 1996-11-29 | Eli Lilly And Company | Use of leukotriene antagonists for alzheimer's disease |
| JPH0940690A (ja) | 1995-05-23 | 1997-02-10 | Yutaka Sashita | ステロイド配糖体及びこれを有効成分とする医薬 |
| AU6714396A (en) | 1995-07-28 | 1997-02-26 | Trustees Of Boston University | Methods and compositions for treating cell proliferative disorders |
| US5977077A (en) | 1995-08-28 | 1999-11-02 | Interlab Corporation | Xanthone analogs for the treatment of infectious diseases |
| US5863904A (en) * | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
| WO1998025616A1 (en) | 1996-12-13 | 1998-06-18 | Eli Lilly And Company | Leukotriene antagonists for cerebral focal stroke |
| WO1998025600A1 (en) | 1996-12-13 | 1998-06-18 | Eli Lilly And Company | Leukotriene antagonists for treatment or inhibition of gout |
| UA47505C2 (uk) | 1996-12-13 | 2002-07-15 | Елі Ліллі Енд Компані | Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну |
| RU2195946C2 (ru) | 1997-03-11 | 2003-01-10 | Ле Лабораториз Аетерна Инк. | Противоопухолевые терапевтические средства, включающие комбинацию экстракта хряща и антинеопластического агента, обеспечивающие высокую эффективность действия при низких токсических побочных эффектах |
| AU6764798A (en) | 1997-03-21 | 1998-10-20 | Eli Lilly And Company | Leukotriene antagonists useful for treating cystic fibrosis |
| WO1998042336A1 (en) | 1997-03-21 | 1998-10-01 | Eli Lilly And Company | Leukotriene antagonists useful for treating gingivitis |
| HUP9904672A2 (hu) | 1997-03-21 | 2000-05-28 | Eli Lilly And Co. | Szájüregi laphámrák ellen alkalmazható leukotrién antagonisták |
| WO1998042346A1 (en) | 1997-03-21 | 1998-10-01 | Eli Lilly And Company | Leukotriene antagonists useful for treating ischemia reperfusion injury |
| US5998454A (en) | 1997-03-21 | 1999-12-07 | Eli Lilly And Company | Leukotriene antagonists useful for treating iritis |
| WO1998042335A1 (en) | 1997-03-21 | 1998-10-01 | Eli Lilly And Company | Leukotriene antagonists useful for treating gout |
| US5914340A (en) | 1997-03-21 | 1999-06-22 | Eli Lilly And Company | Leukotriene antagonists useful for treating dermatoses |
| AU6450898A (en) | 1997-03-21 | 1998-10-20 | Eli Lilly And Company | Leukotriene antagonists useful for treating cerebral focal stroke |
| DE19721211A1 (de) | 1997-05-21 | 1998-11-26 | Lindner Sen Wolfgang Dr Med | Kombination von antientzündlichen Wirkstoffen mit immunstimulierenden Agentien und zytotoxischen Agentien zur Behandlung von Tumoren |
| CN1217698C (zh) | 1998-08-24 | 2005-09-07 | 马克西姆药品公司 | 应用h2受体激动剂和其它t细胞活化剂激活和保护t细胞(cd4+和cd8+) |
| JP2002524481A (ja) | 1998-09-10 | 2002-08-06 | ジェネーラ・コーポレーション | 他の抗癌剤または理学療法と組み合わせたスクアラミンを使用する癌腫の処置 |
| AUPP609198A0 (en) | 1998-09-22 | 1998-10-15 | Curtin University Of Technology | Use of non-peptidyl compounds for the treatment of insulin related ailments |
| US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
| GB9903404D0 (en) | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis |
| ATE289586T1 (de) * | 1999-03-01 | 2005-03-15 | Pfizer Prod Inc | Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor |
| ATE324888T1 (de) | 1999-06-14 | 2006-06-15 | Cancer Rec Tech Ltd | Krebstherapie |
| US6806257B1 (en) * | 1999-10-20 | 2004-10-19 | Board Of Trustees Of Southern Illinois University | Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators |
| HUP0204449A3 (en) | 1999-11-11 | 2006-02-28 | Lilly Co Eli | Oncolytic combinations for the treatment of cancer, containing 2',2'-difluoronucleoside and leukotriene antagonist as active ingredients |
| CA2390789A1 (en) | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| AU1916601A (en) | 1999-11-11 | 2001-06-06 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| AU1916501A (en) | 1999-11-11 | 2001-06-06 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| JP2003522790A (ja) * | 2000-02-17 | 2003-07-29 | メルク エンド カムパニー インコーポレーテッド | Ｃｏｘ−２選択的阻害薬を用いた前立腺癌の治療または予防 |
| JP2001247459A (ja) * | 2000-03-03 | 2001-09-11 | Oakland Uniservices Ltd | 癌の組み合わせ療法 |
| EP1311262A4 (en) * | 2000-07-28 | 2005-06-01 | Cancer Rec Tech Ltd | COMBINED TREATMENT AGAINST CANCER |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2386836B (en) * | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| GB0321999D0 (en) | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
| GT200500186A (es) * | 2004-07-07 | 2006-03-02 | Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits | |
| CA2620436A1 (en) | 2005-08-26 | 2007-03-01 | Antisoma Plc | Combinations comprising dmxaa for the treatment of cancer |
| GB0517387D0 (en) | 2005-08-26 | 2005-10-05 | Antisoma Res Ltd | Combinations for the treatment of cancer |
| US20100286254A1 (en) | 2007-10-23 | 2010-11-11 | Antisoma Research Limited | Crystalline forms of dmxaa sodium salt |
-
2001
- 2001-09-03 GB GBGB0121285.1A patent/GB0121285D0/en not_active Ceased
-
2002
- 2002-09-03 ES ES02758562T patent/ES2321283T3/es not_active Expired - Lifetime
- 2002-09-03 PT PT02758562T patent/PT1423105E/pt unknown
- 2002-09-03 NZ NZ567456A patent/NZ567456A/en not_active IP Right Cessation
- 2002-09-03 NZ NZ576925A patent/NZ576925A/en not_active IP Right Cessation
- 2002-09-03 EP EP10001750A patent/EP2236134A1/en not_active Withdrawn
- 2002-09-03 CN CNA2009101604084A patent/CN101607087A/zh active Pending
- 2002-09-03 EA EA200801611A patent/EA200801611A1/ru unknown
- 2002-09-03 NZ NZ554093A patent/NZ554093A/en not_active IP Right Cessation
- 2002-09-03 BR BR0212258-8A patent/BR0212258A/pt not_active IP Right Cessation
- 2002-09-03 CN CNB028172574A patent/CN100536840C/zh not_active Expired - Fee Related
- 2002-09-03 DE DE60230159T patent/DE60230159D1/de not_active Expired - Lifetime
- 2002-09-03 CA CA002458459A patent/CA2458459A1/en not_active Abandoned
- 2002-09-03 DK DK02758562T patent/DK1423105T3/da active
- 2002-09-03 MX MXPA04002004A patent/MXPA04002004A/es active IP Right Grant
- 2002-09-03 EA EA200601118A patent/EA010857B1/ru not_active IP Right Cessation
- 2002-09-03 NZ NZ546573A patent/NZ546573A/en not_active IP Right Cessation
- 2002-09-03 JP JP2003524567A patent/JP2005509599A/ja not_active Ceased
- 2002-09-03 EP EP02758562A patent/EP1423105B9/en not_active Expired - Lifetime
- 2002-09-03 CN CNA2009101604101A patent/CN101596187A/zh active Pending
- 2002-09-03 EA EA200400370A patent/EA008056B1/ru not_active IP Right Cessation
- 2002-09-03 SI SI200230798T patent/SI1423105T1/sl unknown
- 2002-09-03 WO PCT/GB2002/004025 patent/WO2003020259A2/en not_active Ceased
- 2002-09-03 AU AU2002324143A patent/AU2002324143B2/en not_active Ceased
- 2002-09-03 CN CNA2009101604099A patent/CN101596186A/zh active Pending
- 2002-09-03 CN CNA2006101513931A patent/CN1994287A/zh active Pending
- 2002-09-03 NZ NZ531045A patent/NZ531045A/en not_active IP Right Cessation
- 2002-09-03 IL IL16017802A patent/IL160178A0/xx unknown
- 2002-09-03 AT AT02758562T patent/ATE415963T1/de active
- 2002-09-03 EP EP06077049A patent/EP1759694A3/en not_active Withdrawn
-
2004
- 2004-02-06 IS IS7144A patent/IS7144A/is unknown
- 2004-02-10 ZA ZA200401078A patent/ZA200401078B/en unknown
- 2004-02-10 NO NO20040591A patent/NO20040591L/no unknown
- 2004-03-02 US US10/790,943 patent/US7863322B2/en not_active Expired - Fee Related
-
2006
- 2006-11-03 US US11/592,678 patent/US20070060637A1/en not_active Abandoned
-
2007
- 2007-07-30 US US11/830,668 patent/US7863320B2/en not_active Expired - Fee Related
- 2007-07-30 US US11/830,650 patent/US7868039B2/en not_active Expired - Fee Related
- 2007-07-30 US US11/830,659 patent/US7868040B2/en not_active Expired - Fee Related
- 2007-07-30 US US11/830,677 patent/US7863321B2/en not_active Expired - Fee Related
-
2008
- 2008-12-31 CY CY20081101516T patent/CY1110426T1/el unknown
-
2009
- 2009-06-03 JP JP2009133903A patent/JP2009263371A/ja active Pending
-
2010
- 2010-07-01 JP JP2010151115A patent/JP2010270124A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010270124A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| JP2013534248A5 (enExample) | ||
| JP2014515373A5 (enExample) | ||
| JP2015530389A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2013507415A5 (enExample) | ||
| JP2016006096A5 (enExample) | ||
| JP2020521797A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2009502743A5 (enExample) | ||
| JP2014521735A5 (enExample) | ||
| JP2012532874A5 (enExample) | ||
| JP2001247459A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| JP2015529234A5 (enExample) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2013532729A5 (enExample) | ||
| JP2012236834A5 (enExample) | ||
| JP2013537212A5 (enExample) | ||
| JP2013541583A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2014530181A5 (enExample) |